MedPath

PCLE for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma

Not Applicable
Conditions
Diagnostic Yield of Gastric Neoplasia
Registration Number
NCT02515721
Lead Sponsor
Shandong University
Brief Summary

Early detection of gastric intestinal metaplasia (GIM) intraepithelial neoplasia (IN), and gastric cancer are essential to improve patients' outcomes. This study aims to compare the diagnostic yield of GIM, IN and early gastric cancer (EGC) by iScan combined probe-based confocal laser endomicroscopy (pCLE) and iScan alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
242
Inclusion Criteria
  • aged between 18 and 80;
  • patients with previous pathologic diagnosis of atrophic gastritis, gastric intestinal metaplasia, and low-grade intraepithelial neoplasia;
  • agree to give written informed consent.
Exclusion Criteria
  • Patients with gastrectomy, acute GI bleeding, and known gastric neoplasia;
  • Patients under conditions unsuitable for performing CLE including coagulopathy (prothrombin time <50% of control, partial thromboplastin time >50 s), impaired renal function (creatinine level >1.2 mg/dL), pregnancy or breastfeeding, and known allergy to fluorescein sodium;
  • Inability to provide informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
the diagnostic yield of intestinal metaplasia, intraepithelial neoplasia, and gastric cancer12 months
Secondary Outcome Measures
NameTimeMethod
the biopsy number needed for diagnosis12 months

Trial Locations

Locations (1)

Endoscopic unit of Qilu Hospital Shandong University

🇨🇳

Jinan, Shandong, China

Endoscopic unit of Qilu Hospital Shandong University
🇨🇳Jinan, Shandong, China
Li Yanqing, PhD, MD
Contact
053182169385
liyanqing@sdu.edu.cn
Li Zhen, PhD, MD
Contact
18560086106
lizhenh@hotmail.com
Zuo Xiuli, PhD, MD
Principal Investigator
© Copyright 2025. All Rights Reserved by MedPath